Peptide Weight Loss: How They Work, FDA Status & Results

GLP-1 medications like semaglutide and tirzepatide have produced the most significant weight loss outcomes ever recorded in drug trials — with some patients losing more than 20% of their body weight. But they’re not the only peptides used for fat loss, and they’re not right for everyone.

This guide covers all three classes of weight loss peptides — GLP-1 receptor agonists, growth hormone-releasing peptides, and fat-specific peptides — with clinical evidence, FDA regulatory status as of 2026, and a clear-eyed look at who each class actually suits.

Key takeaways

Semaglutide (Wegovy) produced 14.9% mean weight loss over 68 weeks in the STEP 1 trial (Wilding et al., NEJM, 2021; n=1,961). Tirzepatide (Zepbound) outperformed it with 20.2% mean weight loss at 72 weeks in the head-to-head SURMOUNT-5 trial (NEJM, May 2025).
Only GLP-1 receptor agonists — semaglutide and tirzepatide — carry FDA approval for chronic weight management.
Growth hormone-releasing peptides (CJC-1295, ipamorelin) are FDA Category 2 as of March 2026, with compounding access restricted. A potential reclassification was announced in February 2026 but has not been finalized.
AOD-9604 is a research peptide with no FDA-approved use and no legal compounding pathway. Its evidence base is limited to preliminary studies.
Weight regain after stopping is substantial. The STEP 1 extension study found participants regained two-thirds of lost weight within one year of discontinuing semaglutide.

What are weight loss peptides?

Weight loss peptides are short chains of amino acids — typically 2 to 50 amino acids long — that act on your body’s hormonal signaling systems to influence fat metabolism.

They don’t burn fat directly. Instead, they mimic or stimulate natural hormones that control appetite, blood sugar, growth hormone release, and fat cell activity.

Three distinct peptide classes target weight loss through different biological pathways:

GLP-1 receptor agonists (semaglutide, tirzepatide): Bind to incretin receptors in the brain and pancreas to suppress appetite, slow stomach emptying, and improve insulin sensitivity. These are the only peptides approved by the FDA for obesity management.
Growth hormone-releasing peptides (GHRPs) (CJC-1295, ipamorelin, sermorelin): Stimulate the pituitary gland to release more growth hormone, which activates fat-burning enzymes in fat cells while preserving lean muscle mass.
Fat-specific peptides (AOD-9604): Mimic a fragment of growth hormone that targets fat cells directly, without the broader hormonal effects of full growth hormone.

Evidence grade: PeptideRx rates the evidence for GLP-1 agonists as Grade A (multiple large randomized controlled trials with consistent results), for GHRPs as Grade B (limited human trials with a plausible mechanism), and for AOD-9604 as Grade C (primarily animal data, limited human evidence).

How weight loss peptides work

Pathway 1: GLP-1 receptor activation

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases naturally after a meal. GLP-1 agonist peptides mimic this hormone — but with a much longer duration in your bloodstream.

The result is a three-part effect:

Appetite suppression. GLP-1 binds to receptors in your hypothalamus, the brain’s appetite control center, reducing hunger signals and increasing satiety.

Slower gastric emptying. Food stays in the stomach roughly 35% longer, keeping you full between meals.

Improved blood sugar regulation. GLP-1 enhances glucose-dependent insulin secretion from pancreatic beta cells, improving blood sugar control without the hypoglycemia risk associated with some diabetes medications.

Pathway 2: Pituitary growth hormone stimulation

GHRPs bind to two receptor types in the pituitary gland — GHRH receptors and ghrelin receptors. This triggers a pulse of growth hormone (GH), which then activates hormone-sensitive lipase in your fat cells.

Hormone-sensitive lipase breaks stored triglycerides into free fatty acids your body can use for energy. The key advantage: GH-pathway peptides reduce body fat while preserving lean muscle mass.

GLP-1 agonists reduce total body weight — including some muscle. A SURMOUNT-1 DXA substudy found approximately 25% of weight lost with tirzepatide was lean mass.

Pathway 3: Direct fat cell targeting

Advanced Obesity Drug 9604 (AOD-9604) mimics amino acids 176–191 of the growth hormone molecule. This fragment handles GH’s fat-mobilization activity without binding the full GH receptor — so AOD-9604 targets fat cells without raising IGF-1 levels or affecting blood sugar.

Human evidence for this pathway remains preliminary.

GLP-1 peptides: Semaglutide and tirzepatide

GLP-1 receptor agonists are the only peptides with FDA approval for chronic weight management. Two compounds dominate this class.

Semaglutide (Wegovy / Ozempic)

Semaglutide is a GLP-1 receptor agonist manufactured by Novo Nordisk. It is approved under the brand name Wegovy(2.4 mg weekly subcutaneous injection) for chronic weight management, and Ozempic (up to 1 mg weekly) for Type 2 diabetes.

STEP 1 trial results (Wilding et al., NEJM, 2021; n=1,961):

14.9% mean weight loss with semaglutide 2.4 mg vs. 2.4% with placebo over 68 weeks
86.4% of semaglutide participants achieved at least 5% weight loss
50.5% achieved at least 15% weight loss
Most common side effects: nausea and diarrhea (transient, mild-to-moderate)

A higher-dose formulation is in development. The STEP UP trial (Novo Nordisk, January 2025) reported semaglutide 7.2 mg achieved 20.7% mean weight loss at 72 weeks, outperforming the approved 2.4 mg dose.

Tirzepatide (Zepbound / Mounjaro)

Tirzepatide is a dual GLP-1/GIP receptor agonist — meaning it activates two incretin pathways rather than one. GIP (glucose-dependent insulinotropic polypeptide) is a second gut hormone that also regulates appetite and fat storage. Eli Lilly manufactures tirzepatide as Zepbound (for obesity) and Mounjaro (for Type 2 diabetes).

SURMOUNT-5 head-to-head trial (Aronne et al., NEJM, May 2025; n=751):

Tirzepatide achieved 20.2% mean weight loss vs. semaglutide’s 13.7% at 72 weeks
Tirzepatide was statistically superior for both weight reduction and waist circumference reduction

SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022; n=2,539):

21.3% mean weight loss at 72 weeks (pooled tirzepatide doses) vs. 5.3% with placebo
DXA substudy: approximately 75% of weight lost was fat mass, 25% lean mass

Semaglutide vs. tirzepatide: side-by-side comparison

Factor	Semaglutide (Wegovy)	Tirzepatide (Zepbound)
Mechanism	GLP-1 receptor agonist	Dual GLP-1/GIP receptor agonist
FDA approval	Approved for obesity (2021) + CV risk reduction (2024)	Approved for obesity (2023)
Weight loss (head-to-head)	13.7% at 72 weeks (SURMOUNT-5)	20.2% at 72 weeks (SURMOUNT-5)
Dosing	2.4 mg weekly subcutaneous injection	5, 10, or 15 mg weekly subcutaneous injection
Retail cost	$900–$1,200/month	$900–$1,200/month
Insurance	Covered: BMI ≥30, or ≥27 + comorbidity	Covered: BMI ≥30, or ≥27 + comorbidity

GLP-1 peptides and insulin resistance

GLP-1 peptides do more than reduce body weight. Semaglutide and tirzepatide both improve insulin sensitivity through two mechanisms: enhanced glucose-dependent insulin secretion from pancreatic beta cells, and reduced hepatic glucose production through glucagon suppression.

Clinical trials show HOMA-IR (a standard measure of insulin resistance) improves within 4–8 weeks — independent of weight loss.

For patients with metabolic syndrome, GLP-1 peptides address multiple diagnostic criteria at once: fasting glucose normalization, triglyceride reduction, and modest blood pressure reduction. This makes them the preferred peptide class for metabolic dysfunction beyond simple weight management.

Growth hormone-releasing peptides: CJC-1295, ipamorelin, and sermorelin

Growth hormone-releasing peptides (GHRPs) stimulate the pituitary gland to produce more growth hormone. The GH your body then releases activates hormone-sensitive lipase in fat cells, breaking stored fat into free fatty acids for energy.

GHRPs are prescribed off-label through compounding pharmacies. They are not approved by the FDA for weight loss.

Regulatory note: As of March 2026, CJC-1295 and ipamorelin are FDA Category 2 — meaning compounding access is restricted. A potential reclassification to Category 1 was announced by HHS Secretary Robert F. Kennedy Jr. on February 27, 2026 (via public remarks on The Joe Rogan Experience, Episode #2461). No formal FDA rulemaking has been published. Category 2 remains the current regulatory status. PeptideRx will update this section when formal guidance is published.

GHRP comparison table

Peptide	Mechanism	Common protocol	Target audience	Regulatory status	Estimated monthly cost
CJC-1295 (DAC)	GHRH receptor agonist; extends GH pulse via drug affinity complex	1–2 mg subcutaneous, 2x/week	Body recomposition (fat loss + muscle preservation)	FDA Category 2; compounding restricted	$250–$400
Ipamorelin	Selective ghrelin receptor agonist; minimal cortisol/prolactin elevation	200–300 mcg subcutaneous daily or 5x/week	Fat loss with minimal hormonal disruption	FDA Category 2; compounding restricted	$200–$350
Sermorelin	GHRH analog; shorter half-life	Daily subcutaneous injection	Age-related GH decline (40s–60s)	FDA Category 2; compounding restricted	$200–$300
Tesamorelin	GHRH analog; FDA-approved for HIV lipodystrophy	2 mg daily subcutaneous	Visceral fat (approved for HIV lipodystrophy; off-label otherwise)	FDA-approved for lipodystrophy only	$500–$700

CJC-1295 + ipamorelin: the common GHRP stack

CJC-1295 and ipamorelin are frequently prescribed together because they stimulate GH release through complementary receptor pathways. CJC-1295 activates GHRH receptors for sustained GH elevation; ipamorelin activates ghrelin receptors for pulsatile GH release.

The combination produces a stronger GH response than either peptide alone.

Reported clinical outcomes for this stack include 5–8% body fat reduction over 12–16 weeks, with lean muscle mass preserved. These figures come from clinical practice observations and smaller studies, not large randomized controlled trials.

PeptideRx rates the evidence for GHRPs as Grade B.

Tesamorelin: the visceral fat specialist

Tesamorelin (Egrifta) is the only GHRP with a specific FDA-approved indication: reducing visceral fat in patients with HIV-associated lipodystrophy. Clinical trials in the approved indication showed 15–20% visceral adipose tissue (VAT) reduction.

Some physicians prescribe tesamorelin off-label for non-HIV visceral adiposity. Insurance does not cover off-label use.

Who are GHRPs best suited for?

GHRPs target a different patient profile than GLP-1 agonists:

Body recomposition goals. Patients who want to reduce body fat while preserving or building lean muscle. GLP-1 agonists reduce total body weight including some muscle; GHRPs preferentially target fat tissue.

Stubborn fat at normal-range BMI (22–27 kg/m²). GLP-1 agonists are approved for BMI ≥30 or ≥27 with a comorbidity. GHRPs fill a gap for patients below those thresholds.

Age-related hormone decline (40s–60s). Growth hormone production declines approximately 14% per decade after age 30. GHRPs restore some of that lost signaling.

GHRPs are not appropriate for significant obesity. GLP-1 agonists deliver superior weight reduction for patients who meet obesity diagnostic criteria.

AOD-9604: the fat-specific peptide

AOD-9604 (Advanced Obesity Drug 9604) is a synthetic peptide that mimics amino acids 176–191 of human growth hormone — the region responsible for GH’s fat-mobilization activity. By targeting only this fragment, AOD-9604 acts on fat cells without binding the full GH receptor and without raising IGF-1 levels or affecting blood sugar.

Legal status: AOD-9604 is not approved by the FDA for any human use. It cannot be legally prescribed or compounded by pharmacies. Availability is limited to unregulated online vendors with no manufacturing oversight or purity guarantees. This is not a gray area.

Evidence base: Preliminary Australian studies suggested 3–5% subcutaneous fat reduction, but larger human validation is lacking. Most circulating claims come from anecdotal reports in fitness communities, not published clinical trials.

PeptideRx rates the evidence for AOD-9604 as Grade C.

BPC-157 clarification: Body Protection Compound-157 (BPC-157) is sometimes marketed alongside AOD-9604 for weight loss. BPC-157 has no validated mechanism for fat reduction and no published evidence supporting weight loss effects. Its studied applications are tissue healing and gut health. BPC-157 does not belong in any weight loss protocol.

FDA regulatory status: approved, off-label, and research

The FDA regulatory landscape for weight loss peptides breaks into three tiers. The tier a peptide occupies directly determines your legal access, quality assurance, and insurance eligibility.

Regulatory tier	Peptides	What it means	Quality assurance
FDA-approved for obesity	Semaglutide (Wegovy), Tirzepatide (Zepbound)	Full FDA review; approved for chronic weight management in adults with BMI ≥30 or ≥27 + comorbidity	FDA-regulated manufacturing; prescription required; insurance may cover
FDA-approved for other indication	Semaglutide (Ozempic, for T2D), Tirzepatide (Mounjaro, for T2D), Tesamorelin (Egrifta, for HIV lipodystrophy)	Approved for a different condition; prescribed off-label for weight loss at physician discretion	Same FDA manufacturing standards; insurance covers approved indication only
Off-label via compounding (Category 2)	CJC-1295, ipamorelin, sermorelin	Restricted from compounding as of late 2023; potential reclassification announced Feb 2026, not yet finalized	Compounding pharmacy quality varies; USP 797 compliance required for sterile preparation
Research peptide (not approved)	AOD-9604, BPC-157	Not approved for any human use; cannot be legally prescribed or compounded	No oversight; unregulated vendors; contamination and purity risks

The February 2026 reclassification update

On February 27, 2026, HHS Secretary Robert F. Kennedy Jr. announced that approximately 14 of 19 Category 2 peptides would move back to Category 1, potentially restoring compounding access for GHRPs including CJC-1295 and ipamorelin.

As of March 2026, no formal FDA rulemaking has been published. Category 2 remains the current regulatory status. Compounding availability depends on when — and whether — official reclassification is finalized.

Who is a good candidate?

The right peptide depends on your BMI, comorbidities, body composition goals, and age.

FDA-approved GLP-1 candidates (semaglutide / tirzepatide)

BMI ≥30 kg/m² regardless of other conditions
BMI 27–29.9 kg/m² with at least one weight-related comorbidity: Type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease
Metabolic syndrome with insulin resistance (GLP-1 agonists address multiple metabolic syndrome components simultaneously)
Prior failed weight loss attempts (most insurance plans require documented history)

Off-label GHRP candidates (CJC-1295 / ipamorelin)

Stubborn body fat with normal-range BMI (22–27 kg/m²), where GLP-1 agonists are not indicated
Body recomposition goals: reducing fat while preserving or building lean muscle
Age-related metabolic slowdown in the 40s–60s from declining growth hormone production

GHRPs are not appropriate for significant obesity. GLP-1 agonists deliver superior outcomes in that population.

Contraindications (all weight loss peptides)

Personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome (GLP-1 black box warning)
Active pancreatitis or history of peptide-induced pancreatitis
Pregnancy or breastfeeding
Severe gastroparesis
Active cancer (GHRPs raise IGF-1 levels, which may promote tumor growth)

Side effects and safety

GLP-1 peptide side effects (semaglutide / tirzepatide)

Most side effects are gastrointestinal and improve over time.

Side effect	Frequency	Notes
Nausea	40–50% of patients	Peaks during dose increases; typically resolves after 4–8 weeks
Diarrhea	20–30% of patients	Usually transient
Vomiting	15–25% of patients	Most common during titration phase
Constipation	15–20% of patients	Manage with hydration and fiber

Management: Slow dose titration over 16–20 weeks minimizes GI symptoms for most patients. Smaller meals and ginger supplements can help during the early weeks.

In the STEP 1 trial, 4.5% of semaglutide participants discontinued treatment due to GI events, vs. 0.8% with placebo.

Rare but serious adverse events:

Pancreatitis: Less than 0.5% incidence. Discontinue immediately if severe abdominal pain develops.
Thyroid C-cell tumors: Black box warning based on rodent studies. Human risk is unclear. Contraindicated with personal or family history of medullary thyroid carcinoma.
Gallbladder disease: Increased risk of gallstones and cholecystitis with rapid weight loss.

GHRP side effects (CJC-1295 / ipamorelin)

GHRPs are generally well-tolerated. Reported side effects include:

Side effect	Notes
Injection site reactions	Mild redness and swelling; rotate injection sites
Transient water retention	Common in first 2–4 weeks; resolves as the body adjusts
Joint discomfort / carpal tunnel symptoms	Related to GH-mediated fluid shifts
Increased hunger	Ipamorelin acts on ghrelin receptors, which can temporarily elevate appetite

Ipamorelin is specifically selected over older GHRPs (GHRP-2 and GHRP-6) because it causes minimal cortisol and prolactin elevation.

Medical monitoring requirements

All peptide weight loss protocols require physician oversight before and during treatment.

Before starting: Comprehensive metabolic panel, lipid panel, HbA1c, thyroid function (TSH), fasting glucose, and contraindication screening.

During treatment: Follow-up every 4–12 weeks during GLP-1 dose titration. Weight tracking, blood pressure monitoring, and adverse event surveillance. For GHRPs: periodic IGF-1 levels and fasting glucose.

Stop treatment if: Severe persistent nausea despite management, signs of pancreatitis, thyroid nodules detected, pregnancy, or allergic reaction.

What happens when you stop taking weight loss peptides?

Weight regain after stopping peptide therapy is well-documented and significant.

GLP-1 withdrawal data

The STEP 1 extension study (Wilding et al., Diabetes, Obesity and Metabolism, 2022; PMID: 35441470) followed 327 participants for one year after stopping semaglutide and lifestyle intervention:

Participants regained two-thirds (11.6 percentage points) of lost weight within 52 weeks of stopping
Net weight loss from baseline to week 120 (one year post-treatment): 5.6%, down from 17.3% at week 68
Cardiometabolic improvements — blood pressure, lipids, blood sugar — also reverted toward baseline

Why it happens. GLP-1 peptides suppress appetite by binding to hypothalamic receptors. Stopping reverses that effect. At the same time, metabolic adaptations from weight loss — reduced resting metabolic rate and elevated hunger hormones — persist, creating biological pressure toward regain.

GHRP cessation

Growth hormone levels decline back to baseline over 2–4 weeks after stopping GHRPs. Fat-burning rates decrease correspondingly. The rebound is less pronounced than with GLP-1 agonists, because GHRPs don’t suppress appetite directly. Fat regain still occurs without sustained GH support if caloric balance isn’t maintained.

Maintenance strategies

Establish sustainable habits during therapy. Eating patterns and exercise routines built during treatment are the most durable way to preserve results after stopping.

Consider long-term or lower-dose continuation. Some patients maintain on a reduced GLP-1 dose (e.g., semaglutide 1.7 mg instead of 2.4 mg).

Monitor and intervene early. Track weight and waist circumference after stopping. Restart therapy if significant regain begins.

Accept the chronic disease model. Obesity is a chronic condition. Peptide therapy may require long-term or indefinite use to sustain results — similar to blood pressure or diabetes medications.

Cost, insurance, and access

Peptide tier	Monthly cost	Insurance coverage	Quality oversight
FDA-approved GLP-1s (Wegovy, Zepbound)	$900–$1,200 retail	Yes, with prior authorization: BMI ≥30 or ≥27 + comorbidity + prior weight loss attempts. Copay: $25–$200/month with coverage.	FDA-regulated manufacturing
Compounded GHRPs (CJC-1295, ipamorelin, sermorelin)	$200–$400	Not covered — off-label, not approved for weight loss. Out-of-pocket.	Compounding pharmacy standards (USP 797 for sterile prep); quality varies
Tesamorelin (off-label for visceral fat)	$500–$700	Covered only for HIV lipodystrophy	FDA-regulated manufacturing
Research peptides (AOD-9604)	$150–$300	No coverage; not a legal prescription	No oversight; unregulated vendors; contamination risk

Insurance coverage tips for GLP-1 peptides

Most insurance plans cover Wegovy or Zepbound with prior authorization. To qualify:

Document BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity
Provide evidence of prior weight loss attempts (supervised diet or exercise program, previous medications)
Your physician submits the prior authorization with supporting medical records

Manufacturer savings programs from Novo Nordisk and Eli Lilly can reduce out-of-pocket costs to $25–$550 per month for commercially insured patients. Medicare Part D coverage varies by plan.

Telehealth access

Virtual consultations ($50–$200 for an initial visit) are increasingly common for peptide prescribing. A legitimate telehealth evaluation requires a licensed physician assessment — not just a questionnaire. Verify that the platform uses board-certified physicians and FDA-registered pharmacies.

Next-generation weight loss peptides in clinical trials

The weight loss peptide pipeline includes several compounds with the potential to exceed current options.

Compound	Developer	Mechanism	Clinical stage	Key results	Timeline
Retatrutide	Eli Lilly	Triple agonist (GLP-1 + GIP + glucagon)	Phase 3 (TRIUMPH program)	28.7% weight loss at 12 mg dose, 68 weeks (TRIUMPH-4, Dec 2025)	7 additional Phase 3 readouts expected 2026
Orforglipron	Eli Lilly	Oral GLP-1 receptor agonist (daily pill)	Phase 3 (ATTAIN program; NEJM, Sept 2025)	>18% of participants at highest dose lost ≥20% body weight; first effective oral GLP-1	FDA submission filed; action date May 2026
CagriSema	Novo Nordisk	Semaglutide + cagrilintide (amylin analog)	Phase 3	Dual-pathway appetite suppression	Phase 3 results expected 2026
Survodutide	Boehringer Ingelheim	Dual GLP-1/glucagon agonist	Phase 3	Phase 2 showed weight loss + liver fat reduction	Phase 3 ongoing

Retatrutide

Retatrutide adds glucagon receptor activation to the GLP-1/GIP dual agonism of tirzepatide. The result is the highest weight loss percentage recorded in any Phase 3 trial to date.

The TRIUMPH-4 trial (Eli Lilly, December 2025) reported 28.7% mean weight loss at the 12 mg dose over 68 weeks in patients with obesity and knee osteoarthritis. GI side effects were consistent with other incretins. Eli Lilly expects seven additional Phase 3 readouts by end of 2026.

Orforglipron

Orforglipron could reshape access to GLP-1 therapy. As a daily oral pill rather than a weekly injection, it removes the injection barrier that keeps some patients from starting treatment.

Phase 3 results published in the New England Journal of Medicine (September 2025) confirmed safety and efficacy for weight loss, with additional cardiovascular benefits. Eli Lilly has filed for FDA approval with a target action date in May 2026.

Frequently asked questions

Is BPC-157 useful for weight loss? No. BPC-157 has no validated mechanism for fat reduction and no published evidence supporting weight loss. Its studied applications are tissue healing and gut health. It does not belong in any weight loss protocol.

Will I regain weight after stopping peptides? Yes — weight regain is common. The STEP 1 extension study found semaglutide participants regained two-thirds of lost weight within one year of stopping. GLP-1 peptides suppress appetite through receptor binding; stopping reverses that effect while metabolic adaptations persist. Maintenance strategies include sustainable lifestyle habits, potential lower-dose continuation, and early monitoring.

Can I use peptides if I have Type 2 diabetes? Yes. Semaglutide and tirzepatide are approved for both Type 2 diabetes (as Ozempic/Mounjaro) and obesity (as Wegovy/Zepbound). They improve insulin sensitivity, enhance glucose-dependent insulin secretion, and reduce HbA1c by 1–2% while supporting weight loss. Insurance coverage is often better for patients with a diabetes diagnosis. GHRPs are less appropriate for Type 2 diabetes due to potential blood sugar effects from GH/IGF-1 elevation.

Does insurance cover peptide weight loss? Insurance covers GLP-1 peptides (semaglutide/tirzepatide) for patients meeting criteria: BMI ≥30, or BMI ≥27 with a documented weight-related comorbidity, plus evidence of prior weight loss attempts. Prior authorization is required. Copays range from $25–$200 per month with coverage. Compounded GHRPs and research peptides are not covered.

What are the most common side effects of GLP-1 peptides? Nausea affects 40–50% of patients. It typically peaks during dose increases and diminishes after 4–8 weeks. Other GI effects include diarrhea (20–30%), vomiting (15–25%), and constipation (15–20%). Slow dose titration over 16–20 weeks reduces GI symptoms for most patients.

Can I combine different peptide types? CJC-1295 and ipamorelin are commonly prescribed together under physician supervision for synergistic growth hormone release. Combining GLP-1 agonists with GHRPs is less common — GLP-1 agonists alone are highly effective for obesity, and adding GHRPs increases cost and monitoring requirements. Never combine peptides without medical oversight.

What are the most advanced weight loss peptides in trials right now? Retatrutide (Eli Lilly), a triple GLP-1/GIP/glucagon agonist, achieved 28.7% mean weight loss in the Phase 3 TRIUMPH-4 trial (December 2025) — the highest recorded in any obesity trial. Orforglipron (Eli Lilly) is the first oral GLP-1, with Phase 3 results published in the NEJM (September 2025) and an FDA action date expected in May 2026. CagriSema (Novo Nordisk) combines semaglutide with cagrilintide, an amylin analog, with Phase 3 results expected in 2026.

Considering peptide therapy for weight management? Consult a licensed endocrinologist or obesity medicine specialist to assess your candidacy based on BMI, comorbidities, and treatment goals.

References

Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. PMID: 35441470
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med.2022;387(4):327-340. (SURMOUNT-1)
Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025;393:26-36. (SURMOUNT-5)
Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. PMID: 38078870
Eli Lilly. TRIUMPH-4 Phase 3 Trial Results. Press release, December 11, 2025.
Novo Nordisk. STEP UP Trial Results. Press release, January 17, 2025.
ATTAIN-1 Trial Results (Orforglipron). Published in N Engl J Med, September 2025.
World Anti-Doping Agency. 2025 Prohibited List International Standard.
FDA. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (Category 2). FDA.gov.
HHS Secretary Robert F. Kennedy Jr. Remarks on The Joe Rogan Experience (Episode #2461), February 27, 2026.

Disclaimer: This content is for educational purposes only and does not constitute medical advice. Peptides discussed in this article include both FDA-approved medications and unapproved research compounds. All peptide therapy should be administered under the supervision of a licensed healthcare provider. PeptideRx does not sell peptides or provide medical consultations. Consult a licensed physician before starting any weight loss peptide protocol.

PeptideRx content is medically reviewed by licensed physicians. Our evidence grading system (Grade A/B/C) reflects the quality and quantity of published research, not a recommendation for or against use.